Vanguard Fiduciary Trust’s Fulcrum Therapeutics FULC Stock Holding History
Bought
Maintained
Sold
Other funds holding FULC
EC
TCM
NCM
SCM
Vanguard Fiduciary Trust's FULC Position: Q2 2026 in Review
Vanguard Fiduciary Trust increased its Fulcrum Therapeutics (FULC) stake by 4.8% in Q2 2026, buying an estimated $95.9K and bringing the position to 345,648 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2925.
Vanguard Fiduciary Trust first reported a position in FULC in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.53M in Q1 2026. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.
- Vanguard Fiduciary Trust held 345,648 shares of Fulcrum Therapeutics worth $1.27M as of Q2 2026.
- Vanguard Fiduciary Trust bought 15,764 Fulcrum Therapeutics shares in Q2 2026, an estimated $95.9K.
- Fulcrum Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2925 holding.
- Vanguard Fiduciary Trust first reported a position in Fulcrum Therapeutics in Q1 2026 and has held it in 2 quarters since.
- Vanguard Fiduciary Trust's Fulcrum Therapeutics position peaked at $2.53M in Q1 2026.
- 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.
Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.